Company news

Prescient Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Response to Aware Query

April 11, 2018

PTX-200 Phase 1b Breast Cancer Trial Results

April 9, 2018

March 2018 Investor Presentation

March 18, 2018

December 2017 Appendix 4C - Quarterly

January 31, 2018

Clinical Trial Updates

January 28, 2018

Clinical Hold Lifted on PTX-200 Breast Cancer Trial

December 10, 2017

PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer

November 5, 2017

September 2017 Appendix 4C - Quarterly

October 26, 2017

PTX-100 to Re-enter Trials in Hematology Niche

October 2, 2017

Prescient to resume AML trial

September 3, 2017

Appendix 4E and 2017 Annual Report

August 29, 2017

June 2017 Appendix 4C - Quarterly

July 25, 2017

Novel PTX-100 Cancer Approach Published in Nature

June 18, 2017

Clinical Trial Update

May 28, 2017

PTX Broker Presentation

May 16, 2017

European Patent Granted for PTX-200

May 11, 2017

Kansas University Joins PTXs AML Trial

May 7, 2017

FDA Grants Orphan Drug Designation for PTX-200 in AML

April 30, 2017

March 2017 Appendix 4C - Quarterly

April 27, 2017

Successful Completion of Phase 1b Breast Cancer Trial

April 6, 2017

Three Additional US Patents Granted

March 15, 2017

First Cohort Successfully Completed in Phase 1b/2 AML Trial

March 7, 2017

December 2016 Appendix 4C - Quarterly

January 24, 2017

First Patient Dosed on Phase 1b/2 AML Trial

December 13, 2016

Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation

December 8, 2016

September 2016 Appendix 4C - Quarterly

October 28, 2016

First patient at Moffitt dosed in Phase 1b/2 breast trial

September 26, 2016

Appendix 4E and 2016 Annual Report

August 31, 2016

USPTO Grants Allowances for Two PTX-200 Patents

August 4, 2016

Change to exercise price of options

July 20, 2016

June 2016 Appendix 4C - Quarterly

July 19, 2016

Yale Joins PTXs Phase 1b/2 AML Clinical Trial

June 15, 2016

Replacement Entitlement Offer Prospectus

June 3, 2016

Offer Document

May 18, 2016

PTX Secures $7.0M Capital Raising

May 17, 2016

March 2016 Appendix 4C - Quarterly

April 21, 2016

Executive Management Change

March 30, 2016

Virax Rights Offer Documentation - 25 May 2011

March 30, 2016

VIR201 HIV Vaccine published in AIDS Journal

March 30, 2016

Update on VIR201 HIV Vaccine Clinical Trial

March 30, 2016

Terms Sheet - Skin Cancer

March 30, 2016

Exclusive License with Transgene for Novel Skin Cancer Immun

March 30, 2016

Appendix 4E

March 30, 2016

Appendix 4D (31 Dec 2010) - 25 February 2011

March 30, 2016

TG1042 Update - Melanoma

March 30, 2016

TG1042 Batch Manufacturing Completed - 26 July 2011

March 30, 2016

Suspension from Official Quotation - VHLG

March 30, 2016

Rights Offer - 19 July 2011

March 30, 2016

Dutchess Continuous Investment Agreement - 10 January 2012

March 30, 2016

Virax to acquire advanced cancer platform from Yale Uni

March 30, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 44 decks. Every deck is listed under its year.